DFE Pharma appoints Peter Rose as new Chief Operating Officer
The appointment reinforces DFE Pharma’s commitment to reliable supply, scalable operations and continuous improvement.
DFE Pharma, a global leader in pharmaceutical excipients, has appointed Peter Rose as Chief Operating Officer, effective 1 September, when he also joined the company’s Leadership Team. He succeeds Teun Heijnen, who will retire at the end of 2026.
Peter brings more than two decades of pharmaceutical experience, having started his career in the dairy sector. He most recently served as Vice President and Managing Director at LGC, and previously held senior manufacturing and operations roles, heading complex operations units and greenfield projects.
According to DFE Pharma, he is known for turning operational challenges into scalable solutions that improve efficiency, quality and delivery, and for a pragmatic, hands-on leadership style that encourages team ownership and continuous improvement.
“Operational excellence is central to how we deliver on our promises to customers,” said Sven Abend, CEO of DFE Pharma. “Peter’s experience in building strong operations teams, improving performance, and driving practical innovation will help us further strengthen reliability, agility, and customer focus across our organization. His leadership approach is strongly aligned with our value of ‘Better every day’: continuously improving, taking accountability, and delivering meaningful value for customers and, ultimately, patients.”
DFE Pharma said it thanks Heijnen for his service and plans to mark his achievements ahead of his retirement at the end of 2026.
